Gemopatrilat
Appearance
Clinical data | |
---|---|
Other names | BMS-189921 |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H26N2O4S |
Molar mass | 378.49 g·mol−1 |
3D model (JSmol) | |
| |
|
Gemopatrilat (INN)[1] is an experimental drug that was never marketed.[2] It acts as a vasopeptidase inhibitor.[3][4] It inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase (neprilysin).[5]
References
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 46" (PDF). World Health Organization. p. 200. Retrieved 2 March 2017.
- ^ "Gemopatrilat". AdisInsight.
Highest Development Phases: Discontinued
- ^ Laverman, GD; Van Goor, H; Henning, RH; De Jong, PE; De Zeeuw, D; Navis, G (January 2003). "Renoprotective Effects of VPI Versus ACEI in Normotensive Nephrotic Rats on Different Sodium Intakes". Kidney International. 63 (1): 64–71. doi:10.1046/j.1523-1755.2003.00708.x. PMID 12472769. Retrieved 2 March 2017.
- ^ Wait, JC; Vaccharajani, N; Mitroka, J; Jemal, M; Khan, S; Bonacorsi, SJ; Rinehart, JK; Iyer, RA (June 2006). "Metabolism of [14C]Gemopatrilat After Oral Administration to Rats, Dogs, and Humans". Drug Metabolism and Disposition. 34 (6): 961–70. doi:10.1124/dmd.105.007500. PMID 16540589.
- ^ Hubner, RA; Kubota, E; Casley, DJ; Johnston, CI; Burrell, LM (May 2001). "In-vitro and in-vivo Inhibition of Rat Neutral Endopeptidase and Angiotensin Converting Enzyme with the Vasopeptidase Inhibitor Gemopatrilat". Journal of Hypertension. 19 (5): 941–6. doi:10.1097/00004872-200105000-00015. PMID 11393678.